CCS Research Featured in the British Journal of Cancer

We are excited to announce a landmark publication just released in the British Journal of Cancer! A link to the article can be found here.

Led by Children’s Cancer Therapy Development Institute (cc-TDI) researchers, this international collaboration uncovered the genetic makeup and underpinnings of a cancer of adolescents and young adults called Clear Cell Sarcoma (CCS). Clear cell sarcoma occurs in both the gastrointestinal tract and the soft tissues like muscle.

This study originated with a conversation between Drs. Patrick Schoffski and Dr. Agnieszka Wozniak at the Leuven Cancer Institute and the team at cc-TDI regarding a patient in need, but quickly evolved into a collaboration. This global team included the Leuven Cancer Institute (Belgium), Seattle Children’s Hospital, Massachusetts General Hospital, and Harvard University (US), the National Cancer Center Research Institute, 宮崎大学 University of Miyazaki and Japanese Foundation for Cancer Research (Japan), Petrov National Medicine Research Center of Oncology (Russia), Instituto Valenciano de Oncología and Patologika Laboratorio (Spain), University of Toronto, The Mount Sinai Hospital and Lunenfeld-Tanenbaum Research Institute (Canada), and The Royal Marsden Hospital and The Institute of Cancer Research (UK). Companies participating included Atomwise and Omics Data Automation.

Highlights of the study include having defined the major genetic differences between CCS of the gastrointestinal tract versus the soft tissues like muscle, with the added but key observation that both subtypes express HER3 proteins. Using a clinical investigation grade antibody drug conjugate patritumab deruxtecan, researchers could show a dose-dependent therapeutic effect on CCS cancer cells in petri dishes. “Additional studies further defining the percentage of CCS patients with HER3 in their tumors, as well as drug testing in animals, are warranted before considering a clinical trial. However, for a disease that up to this point has no treatment when the disease has spread beyond the original site, this avenue of research is promising” says Dr. Charles Keller, senior author of the study. “It was amazing how physicians and researchers around the world came together for this study – a beautiful example of open science without borders,” says Samuel Rasmussen, the cc-TDI mechanical engineer who systematically directed these studies.

The collaboration was inspired by the parents of Sara, a young woman with clear cell sarcoma and a survivor of the disease (Clear Cell Sarcoma Foundation). Important aspects of this study were funded by the Rucker Collier Foundation for sclerosing epithelioid sarcoma (SEF), a sarcoma with a highly related genetic fusion gene, EWSR1-CREB3L1, which is reminiscent of the EWSR1-CREB1 fusion sometimes found in CCS. Other funding was provided by Golf Fights Cancer in honor of Peter Fox. The Sam Day Foundation provided funding for patient sample processing and sequencing through cc-TDI’s CuReFast program. Thank you to everyone involved for making this critical research possible!

Share this post
Share on facebook
Share on google
Share on twitter
Share on linkedin